Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment;Quelle imagerie pour la prise en charge de la rechute biochimique du cancer de la prostate: TEP ou IRM?

Cancer/Radiotherapie

Volumn 18, Issue 5-6, 2014, Pages 509-516

  Cochet, A ^a,b,c   Kanoun, S ^a,b   Humbert, O ^a,b,c   Walker, P M ^b,c   Cormier, L ^c   Crehange G ^a,b   Brunotte, F ^a,b,c  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Biochemical failure; Multimodality MRI; PET; Prostate cancer

Indexed keywords

CANCER RECURRENCE; CANCER STAGING; HUMAN; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; SHORT SURVEY; TREATMENT FAILURE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; BLOOD; BRACHYTHERAPY; DIAGNOSTIC USE; LYMPH NODE METASTASIS; MALE; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SCINTISCANNING; SECONDARY; TUMOR RECURRENCE;

CARBON; CHOLINE; FLUORINE; FLUOROCHOLINE; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT;

ADENOCARCINOMA; BRACHYTHERAPY; CARBON RADIOISOTOPES; CHOLINE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SALVAGE THERAPY;

EID: 84907408784     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2014.07.148     Document Type: Short Survey

References (82)

1. Grossfeld G.D., Latini D.M., Lubeck D.P., Mehta S.S., Carroll P.R. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003, 169:157-163.
2. Stephenson A.J., Kattan M.W., Eastham J.A., Dotan Z.A., Bianco F.J., Lilja H., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006, 24:3973-3978.
3. Roach M., Hanks G., Thames H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
4. Bhattasali O., Chen L.N., Tong M., Lei S., Collins B.T., Krishnan P., et al. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naive prostate cancer. Front Oncol 2013, 3:293.
5. Sartor C.I., Strawderman M.H., Lin X.H., Kish K.E., McLaughlin P.W., Sandler H.M. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997, 38:941-947.
6. Kane C.J., Amling C.L., Johnstone P.A., Pak N., Lance R.S., Thrasher J.B., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003, 61:607-611.
7. Barentsz J.O., Richenberg J., Clements R., Choyke P., Verma S., Villeirs G., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757.
8. Muller B.G., Futterer J.J., Gupta R.T., Katz A., Kirkham A., Kurhanewicz J., et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int 2014, 113:218-227.
9. O'Connor J.P., Jackson A., Parker G.J., Roberts C., Jayson G.C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012, 9:167-177.
10. Malayeri A.A., El Khouli R.H., Zaheer A., Jacobs M.A., Corona-Villalobos C.P., Kamel I.R., et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics 2011, 31:1773-1791.
11. Kwock L., Smith J.K., Castillo M., Ewend M.G., Collichio F., Morris D.E., et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 2006, 7:859-868.
12. Costello L.C., Franklin R.B. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998, 35:285-296.
13. Kurhanewicz J., Swanson M.G., Nelson S.J., Vigneron D.B. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002, 16:451-463.
14. Coakley F.V., Teh H.S., Qayyum A., Swanson M.G., Lu Y., Roach M., et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004, 233:441-448.
15. Portalez D., Mozer P., Cornud F., Renard-Penna R., Misrai V., Thoulouzan M., et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012, 62:986-996.
16. Schoder H., Herrmann K., Gonen M., Hricak H., Eberhard S., Scardino P., et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005, 11:4761-4769.
17. Jadvar H. FDG PET in prostate cancer. PET clin 2009, 4:155-161.
18. Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998, 39:990-995.
19. DeGrado T.R., Baldwin S.W., Wang S., Orr M.D., Liao R.P., Friedman H.S., et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42:1805-1814.
20. 2 kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296:580-583.
21. Calabria F., Chiaravalloti A., Schillaci O. (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer. Clin Nucl Med 2014, 39:122-130.
22. Dost R.J., Glaudemans A.W., Breeuwsma A.J., de Jong I.J. Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2013, 40:S41-S47.
23. Soloviev D., Fini A., Chierichetti F., Al-Nahhas A., Rubello D. PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 2008, 35:942-949.
24. Larson S.M., Morris M., Gunther I., Beattie B., Humm J.L., Akhurst T.A., et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004, 45:366-373.
25. Toth G., Lengyel Z., Balkay L., Salah M.A., Tron L., Toth C. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol 2005, 173:66-69.
26. Schuster D.M., Votaw J.R., Nieh P.T., Yu W., Nye J.A., Master V., et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007, 48:56-63.
27. Dijkgraaf I., Franssen G.M., McBride W.J., D'Souza C.A., Laverman P., Smith C.J., et al. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med 2012, 53:947-952.
28. O'Donoghue J.A., Zanzonico P., Pugachev A., Wen B., Smith-Jones P., Cai S., et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61:1493-1502.
29. McParland B.J., Wall A., Johansson S., Sorensen J. The clinical safety, biodistribution and internal radiation dosimetry of [(1)(8)F]fluciclovine in healthy adult volunteers. Eur J Nucl Med Mol Imaging 2013, 40:1256-1264.
30. Nanni C., Schiavina R., Boschi S., Ambrosini V., Pettinato C., Brunocilla E., et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging 2013, 40:S11-S17.
31. Bortot D.C., Amorim B.J., Oki G.C., Gapski S.B., Santos A.O., Lima M.C., et al. (1)(8)F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging 2012, 39:1730-1736.
32. Pfitzenmaier J., Pahernik S., Tremmel T., Haferkamp A., Buse S., Hohenfellner M. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?. BJU Int 2008, 102:1413-1418.
33. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014, 65:467-479.
34. Vargas H.A., Wassberg C., Akin O., Hricak H. MR imaging of treated prostate cancer. Radiology 2012, 262:26-42.
35. Deliveliotis C., Manousakas T., Chrisofos M., Skolarikos A., Delis A., Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol 2007, 25:309-313.
36. Casciani E., Polettini E., Carmenini E., Floriani I., Masselli G., Bertini L., et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol 2008, 190:1187-1192.
37. Cirillo S., Petracchini M., Scotti L., Gallo T., Macera A., Bona M.C., et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009, 19:761-769.
38. Wu L.M., Xu J.R., Gu H.Y., Hua J., Zhu J., Chen J., et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol) 2013, 25:252-264.
39. Sciarra A., Salciccia S., Panebianco V. Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging. Eur Urol 2008, 54:485-488.
40. Reske S.N., Blumstein N.M., Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008, 35:9-17.
41. Castellucci P., Fuccio C., Rubello D., Schiavina R., Santi I., Nanni C., et al. Is there a role for (1)(1)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase<1.5ng/mL?. Eur J Nucl Med Mol Imaging 2011, 38:55-63.
42. Castellucci P., Ceci F., Graziani T., Schiavina R., Brunocilla E., Mazzarotto R., et al. Early biochemical relapse after radical prostatectomy: which prostate cancer patient may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?. J Nucl Med 2014.
43. Giovacchini G., Picchio M., Briganti A., Cozzarini C., Scattoni V., Salonia A., et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010, 184:938-943.
44. Giovacchini G., Picchio M., Garcia-Parra R., Mapelli P., Briganti A., Montorsi F., et al. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol 2013, 189:105-110.
45. Castellucci P., Fuccio C., Nanni C., Santi I., Rizzello A., Lodi F., et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009, 50:1394-1400.
46. Bauman G., Belhocine T., Kovacs M., Ward A., Beheshti M., Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012, 15:45-55.
47. Heinisch M., Dirisamer A., Loidl W., Stoiber F., Gruy B., Haim S., et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA<5ng/mL?. Mol Imaging Biol 2006, 8:43-48.
48. Pelosi E., Arena V., Skanjeti A., Pirro V., Douroukas A., Pupi A., et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008, 113:895-904.
49. Alfarone A., Panebianco V., Schillaci O., Salciccia S., Cattarino S., Mariotti G., et al. Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol 2012, 84:109-121.
50. Kitajima K., Murphy R.C., Nathan M.A., Froemming A.T., Hagen C.E., Takahashi N., et al. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med 2014, 55:223-232.
51. Panebianco V., Sciarra A., Lisi D., Galati F., Buonocore V., Catalano C., et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2012, 81:700-708.
52. Pucar D., Hricak H., Shukla-Dave A., Kuroiwa K., Drobnjak M., Eastham J., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69:62-69.
53. Rouviere O., Valette O., Grivolat S., Colin-Pangaud C., Bouvier R., Chapelon J.Y., et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-Correlation with biopsy findings. Urology 2004, 63:922-927.
54. Pucar D., Shukla-Dave A., Hricak H., Moskowitz C.S., Kuroiwa K., Olgac S., et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005, 236:545-553.
55. Westphalen A.C., Coakley F.V., Roach M., McCulloch C.E., Kurhanewicz J. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology 2010, 256:485-492.
56. Sala E., Akin O., Moskowitz C.S., Eisenberg H.F., Kuroiwa K., Ishill N.M., et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006, 238:929-937.
57. Bomers J.G., Yakar D., Overduin C.G., Sedelaar J.P., Vergunst H., Barentsz J.O., et al. MR imaging-guided focal cryoablation in patients with recurrent prostate cancer. Radiology 2013, 268:451-460.
58. Hsu C.C., Hsu H., Pickett B., Crehange G., Hsu I.C., Dea R., et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:370-377.
59. Breeuwsma A.J., Pruim J., van den Bergh A.C., Leliveld A.M., Nijman R.J., Dierckx R.A., et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010, 77:160-164.
60. Ceci F., Castellucci P., Graziani T., Schiavina R., Brunocilla E., Mazzarotto R., et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 2014, 41:878-886.
61. Chondrogiannis S., Marzola M.C., Ferretti A., Maffione A.M., Rampin L., Grassetto G., et al. Role of (1)(8)F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013, 40:1356-1364.
62. Piccardo A., Paparo F., Picazzo R., Naseri M., Ricci P., Marziano A., et al. Value of fused (18) F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after ebrt: preliminary results. Biomed Res Int 2014, 2014:103718.
63. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
64. Rouvière O. Imaging techniques for local recurrence of prostate cancer: for whom, why and how?. Diagn Interv Imaging 2012, 93:279-290.
65. Weichselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8:378-382.
66. Corbin K.S., Hellman S., Weichselbaum R.R. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013, 31:1384-1390.
67. Eiber M., Holzapfel K., Ganter C., Epple K., Metz S., Geinitz H., et al. including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 2011, 33:1160-1170.
68. Luboldt W., Kufer R., Blumstein N., Toussaint T.L., Kluge A., Seemann M.D., et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008, 249:1017-1025.
69. Birkhauser F.D., Studer U.E., Froehlich J.M., Triantafyllou M., Bains L.J., Petralia G., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013, 64:953-960.
70. Ross R.W., Zietman A.L., Xie W., Coen J.J., Dahl D.M., Shipley W.U., et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009, 33:301-305.
71. Picchio M., Briganti A., Fanti S., Heidenreich A., Krause B.J., Messa C., et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011, 59:51-60.
72. Umbehr M.H., Muntener M., Hany T., Sulser T., Bachmann L.M. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013, 64:106-117.
73. Giovacchini G., Picchio M., Coradeschi E., Bettinardi V., Gianolli L., Scattoni V., et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:301-309.
74. Scattoni V., Picchio M., Suardi N., Messa C., Freschi M., Roscigno M., et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52:423-429.
75. Schilling D., Schlemmer H.P., Wagner P.H., Bottcher P., Merseburger A.S., Aschoff P., et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008, 102:446-451.
76. Tilki D., Reich O., Graser A., Hacker M., Silchinger J., Becker A.J., et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013, 63:792-796.
77. Picchio M., Berardi G., Fodor A., Busnardo E., Crivellaro C., Giovacchini G., et al. (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014, 41:1270-1279.
78. Schiavina R., Martorana G. The promise of choline-PET/CT in the detection of recurrent prostate cancer: what are the limits of our investigation?. Eur Urol 2013, 63:797-799.
79. Picchio M., Spinapolice E.G., Fallanca F., Crivellaro C., Giovacchini G., Gianolli L., et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012, 39:13-26.
80. Kjolhede H., Ahlgren G., Almquist H., Liedberg F., Lyttkens K., Ohlsson T., et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012, 110:1501-1506.
81. Soyka J.D., Muster M.A., Schmid D.T., Seifert B., Schick U., Miralbell R., et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2012, 39:936-943.
82. Giovacchini G., Picchio M., Garcia-Parra R., Briganti A., Abdollah F., Gianolli L., et al. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med 2014, 55:233-241.